peptide sciences. FAQ

The Peptide Sciences shut down does not mean the peptide market has disappeared. It means that the vendor landscape has thinned and due diligence matters more than it did before. Here is what to look for when evaluating a replacement supplier.

To understand why Peptide Sciences shut down, you have to zoom out and look at the broader regulatory environment. The research peptide market has been under increasing pressure for several years. But starting in late 2023, enforcement began accelerating. The FDA added 19 peptides to its Category 2 list, which effectively prohibited licensed compounding pharmacies from preparing them. The list included BPC-157 , TB-500, and other widely used compounds. The agency cited concerns about immunogenicity, manufacturing impurities, and the absence of formal clinical trial data in its decision. In March 2024, Eli Lilly filed an International Trade Commission complaint against twelve vendors selling imported tirzepatide. By January 2025, the ITC issued a General Exclusion Order blocking all trademark-infringing tirzepatide imports. That same month, the FDA declared the semaglutide shortage resolved, removing the legal compounding exemption that had allowed pharmacies to prepare it. By December 2024, the FDA had issued warning letters to four peptide vendors directly: Prime Peptides, Xcel Peptides, SwissChems, and Summit Research. In June 2025, the FDA raided the warehouse of Amino Asylum, taking the site offline. The message being sent to every vendor operating in this space was unambiguous. Peptide Sciences appears to have read that environment and made a calculated decision to exit before becoming the subject of an enforcement action. Whether additional legal pressure was applied privately is not publicly known, but the timing and the terse voluntary closure statement are consistent with a company retreating from an increasingly untenable position.

For many buyers, Peptide Sciences was the first name that came up when looking for research peptides in the United States. The company built its reputation on a broad catalog that covered most of the compounds circulating in the research community. That included growth hormone secretagogues, tissue repair peptides, fat-loss compounds, and later GLP-1 analogues like semaglutide and retatrutide. Compared to smaller vendors, the site looked polished and professional. Orders typically shipped on time, packaging was consistent, and customer service generally responded when issues came up. That combination of presentation and reliability made Peptide Sciences something of a default option. In a market where quality can vary wildly, it was often viewed as one of the safer starting points. Like most companies operating in the space, the products were labeled strictly as research chemicals and not intended for human consumption.

The official message left on the Peptide Sciences homepage was extremely brief. It read: That was the entire announcement. No timeline, explanation, or guidance for customers with open orders or store credit. Support channels also stopped responding around the same time, leaving tons of customers unsure whether pending transactions would be completed. The wording of that message matters. The company described the shutdown as voluntary , but within the context of what has been happening across the peptide industry, most observers interpret that phrase differently. In many cases, “voluntary” closures happen when companies recognize that enforcement action is likely and choose to exit before regulators force the issue.

Disclaimer: Muscle and Brawn is an informational resource. This article does not constitute legal, medical, or purchasing advice. The regulatory landscape described reflects information available as of March 2026 and is subject to change. Peptide use outside of licensed medical channels carries legal and health risks. Consult a licensed physician before beginning any peptide protocol.

The honest answer is that we don’t know, but we aren’t keeping our hopes up. When a vendor in this space shuts down abruptly without a transition plan or public communication, customers with outstanding orders or store balances are typically left with no recourse. Peptide Sciences has not announced any refund process or timeline. If you placed an order that was not fulfilled, your best option is to contact your bank or credit card provider and dispute the charge as soon as possible. Depending on how much time has passed since the transaction and the policies of your financial institution, a chargeback may still be possible.

Custom synthesis is available for research teams requiring proprietary sequences or analogs. Real Peptides handles custom orders with the same synthesis and testing standards as catalog compounds. Full HPLC, MS, and AAA verification included. Turnaround time for custom peptides is 3–4 weeks from sequence confirmation, with batch sizes starting at 10 mg. Contact us through realpeptides.co with your sequence and purity requirements for a detailed quote.

Order from a pre-vetted peptide sciences alternative before you run out. Waiting until stock depletion forces you to accept whatever's available fastest. Real Peptides maintains standing inventory for high-demand compounds like Thymalin and MK 677, specifically to cover gaps when other suppliers backorder. Establish a secondary vendor relationship now. Not mid-protocol when delays cost weeks of data.

Contact the supplier immediately before using it. Differences in lyophilized cake appearance (color, texture, dissolution time) can indicate synthesis pathway differences that don't affect purity but do affect handling. Real Peptides documents expected appearance for every compound. If your batch looks different from the specification, we investigate before you waste it. Turbidity, unexpected color, or incomplete dissolution are red flags requiring mass spec verification.

Request full synthesis documentation from Real Peptides, including protecting group methodology, coupling reagent specifications, and cleavage conditions. This information is archived and provided within 48 hours. Peptide Sciences treats synthesis pathways as proprietary, providing only standard certificates of analysis with purity, molecular weight, and retention time. If journal reviewers request synthesis methodology to assess reproducibility, Real Peptides' transparency eliminates a potential publication roadblock.

Contact your supplier immediately with the certificate of analysis and your experimental observations. Real Peptides will cross-reference your lot number against synthesis records and third-party test results. If contamination is confirmed, replacement product from a verified clean batch ships within 24 hours. Peptide Sciences' sample-based testing means your specific vial may not have been individually tested, requiring you to ship a sample back for independent verification before replacement, which adds 5–7 days to resolution.

Submit a custom synthesis request with the exact amino acid sequence and desired purity threshold. Real Peptides accepts orders as small as 50mg with 4–6 week turnaround, making it viable for initial feasibility testing. Peptide Sciences requires 100mg minimums and 6–8 weeks, which works better if you've already validated the sequence and need larger quantities. For novel sequences where you're uncertain about optimal dosing or solubility, Real Peptides' lower minimum reduces upfront cost risk.

Lock in peptide supply from a single batch if possible, or request synthesis protocol consistency guarantees from your supplier. Real Peptides' small-batch model means fewer units per synthesis run, but the company archives synthesis conditions and can replicate exact protocols for subsequent batches. Peptide Sciences' high-volume production offers better odds of securing 12+ months of supply from a single batch, but protocol replication across batches is less granular due to proprietary synthesis details.